http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Optical coding of fusion genes using multicolor quantum dots for prostate cancer diagnosis
Lee, Hyojin,Kim, Chloe,Lee, Dongjin,Park, Jea Ho,Searson, Peter C,Lee, Kwan Hyi DOVE MEDICAL PRESS 2017 INTERNATIONAL JOURNAL OF NANOMEDICINE Vol.12 No.-
<P>Recent studies have found that prostate cancer expresses abnormal genetic markers including multiple types of <I>TMPRSS2–ERG</I> fusion genes. The expression level of different <I>TMPRSS2–ERG</I> fusion genes is correlated to pathologic variables of aggressive prostate cancer and disease progression. State-of-the-art methods for detection of <I>TMPRSS2–ERG</I> fusion genes include reverse transcription polymerase chain reaction (RT-PCR) with a detection limit of 1 fmol at urinary condition. RT-PCR is time consuming, costly, and inapplicable for multiplexing. Ability to identify multiple fusion genes in a single sample has become important for diagnostic and clinical purposes. There is a need for a sensitive diagnostic test to detect multiple <I>TMPRSS2–ERG</I> fusion genes for an early diagnosis and prognosis of prostate cancer. Here, we propose to develop an assay for prostate cancer diagnosis using oligonucleotide-functionalized quantum dot and magnetic microparticle for optical detection of rearranged <I>TMPRSS2–ERG</I> fusion genes at a low concentration in urine. We found that our assay was able to identify three different types of fusion gene with a wide detection range and detection limit of 1 fmol (almost the same level of the RT-PCR result reported). Here, we show detection of multiple <I>TMPRSS2–ERG</I> fusion genes using color-coded oligonucleotides in cell lysate and urine.</P>
Diagnosis of prostate cancer via nanotechnological approach
Kang, Benedict J,Jeun, Minhong,Jang, Gun Hyuk,Song, Sang Hoon,Jeong, In Gab,Kim, Choung-Soo,Searson, Peter C,Lee, Kwan Hyi Dove Medical Press 2015 INTERNATIONAL JOURNAL OF NANOMEDICINE Vol.10 No.-
<P>Prostate cancer is one of the leading causes of cancer-related deaths among the Caucasian adult males in Europe and the USA. Currently available diagnostic strategies for patients with prostate cancer are invasive and unpleasant and have poor accuracy. Many patients have been overly or underly treated resulting in a controversy regarding the reliability of current conventional diagnostic approaches. This review discusses the state-of-the-art research in the development of novel noninvasive prostate cancer diagnostics using nanotechnology coupled with suggested diagnostic strategies for their clinical implication.</P>
Lee, Keon ,Yong,Jang, Gun ,Hyuk,Byun, Cho ,Hyun,Jeun, Minhong,Searson, Peter ,C.,Lee, Kwan ,Hyi Portland Press Ltd. 2017 Bioscience reports Vol.37 No.3
<P>Preclinical screening with animal models is an important initial step in clinical translation of new drug delivery systems. However, establishing efficacy, biodistribution, and biotoxicity of complex, multicomponent systems in small animal models can be expensive and time-consuming. Zebrafish models represent an alternative for preclinical studies for nanoscale drug delivery systems. These models allow easy optical imaging, large sample size, and organ-specific studies, and hence an increasing number of preclinical studies are employing zebrafish models. In this review, we introduce various models and discuss recent studies of nanoscale drug delivery systems in zebrafish models. Also in the end, we proposed a guideline for the preclinical trials to accelerate the progress in this field.</P>
Dawidczyk, C.M.,Kim, C.,Park, J.H.,Russell, L.M.,Lee, K.H.,Pomper, M.G.,Searson, P.C. Elsevier Science Publishers 2014 Journal of controlled release Vol.187 No.-
The ability to efficiently deliver a drug to a tumor site is dependent on a wide range of physiologically imposed design constraints. Nanotechnology provides the possibility of creating delivery vehicles where these design constraints can be decoupled, allowing new approaches for reducing the unwanted side effects of systemic delivery, increasing targeting efficiency and efficacy. Here we review the design strategies of the two FDA-approved antibody-drug conjugates (Brentuximab vedotin and Trastuzumab emtansine) and the four FDA-approved nanoparticle-based drug delivery platforms (Doxil, DaunoXome, Marqibo, and Abraxane) in the context of the challenges associated with systemic targeted delivery of a drug to a solid tumor. The lessons learned from these nanomedicines provide an important insight into the key challenges associated with the development of new platforms for systemic delivery of anti-cancer drugs.